Loading
KDM5C (Lysine-specific demethylase 5C) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Head and neck squamous cell carcinoma, Ovarian cancer and 5 more.
Histone demethylase that specifically demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-9', H3 'Lys-27', H3 'Lys-36', H3 'Lys-79' or H4 'Lys-20'. Demethylates trimethylated and dimethylated but not monomethylated H3 'Lys-4'.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Everolimus, Capivasertib and Sunitinib. Open Targets scores its association with cancer at 0.74 (direct and indirect evidence; datatypes literature 0.98, animal model 0.44, genetic association 0.00, somatic mutation 0.96). IntOGen calls it a driver in 10 cohorts (1 activating, 9 loss-of-function), covering Renal Clear Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Lung Adenocarcinoma, Ovarian Epithelial Tumour, Pancreatic Adenocarcinoma, Plasma Cell Myeloma and others.
In plain words · KDM5C (Lysine-specific demethylase 5C) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Head and neck squamous cell carcinoma, Ovarian cancer and 5 more.
KDM5C (Lysine-specific demethylase 5C) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Head and neck squamous cell carcinoma, Ovarian cancer and 5 more.
Histone demethylase that specifically demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-9', H3 'Lys-27', H3 'Lys-36', H3 'Lys-79' or H4 'Lys-20'.
No product in this corpus aims at KDM5C yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA KDM5C: RNA low tissue specificity; no normal tissue stained high. Distribution: 7 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Renal cell carcinoma, Head and neck squamous cell carcinoma, Ovarian cancer, Pancreatic ductal adenocarcinoma, Multiple myeloma, Skin cancer (all types), Colorectal cancer); Open Targets associates it with 1 specific cancer type at or above 0.5 (clear cell renal carcinoma). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P41229; CIViC gene KDM5C; IntOGen KDM5C; Human Protein Atlas KDM5C tissue; Open Targets ENSG00000126012 associations
First described 1994. Earliest sequence paper UniProt cites for the protein: Wu et al, Hum. Mol. Genet, 1994, "Isolation and characterization of XE169, a novel human gene that escapes X-inactivation". Source.
Sources: HGNC HGNC:11114 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P41229 (protein name, function text, keywords and locations (REST API)); CIViC gene KDM5C (2 evidence items, 0 assertions, 2 variants; diseases: Oestrogen Receptor-positive Breast Cancer, Renal Cell Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000126012 (association with cancer (MONDO_0004992) 0.74; per-cancer scores at or above 0.5: colorectal cancer 0.53, renal cell carcinoma 0.68, skin cancer 0.54 (GraphQL API, CC0)); IntOGen KDM5C (driver in 10 cohorts (Act 1, LoF 9); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Histone demethylase that specifically demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-9', H3 'Lys-27', H3 'Lys-36', H3 'Lys-79' or H4 'Lys-20'. Demethylates trimethylated and dimethylated but not monomethylated H3 'Lys-4'. Participates in transcriptional repression of neuronal genes by recruiting histone deacetylases and REST at neuron-restrictive silencer elements. Represses the CLOCK-BMAL1 heterodimer-mediated transcriptional activation of the core clock component PER2. Location: Nucleus (UniProt). Locus Xp11.22 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"KDM5C" OR ABSTRACT:"KDM5C" OR TITLE:"lysine demethylase 5C" OR ABSTRACT:"lysine demethylase 5C" OR TITLE:"Lysine-specific demethylase 5C" OR ABSTRACT:"Lysine-specific demethylase 5C" OR TITLE:"DXS1272E" OR ABSTRACT:"DXS1272E" OR TITLE:"XE169" OR ABSTRACT:"XE169" OR TITLE:"JARID1C" OR ABSTRACT:"JARID1C") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KDM5C, not a curated reading list.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, CIViC, IntOGen.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, Skin cancer (all types), IntOGen.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, Skin cancer (all types), IntOGen.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, Skin cancer (all types), IntOGen.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, Skin cancer (all types), IntOGen.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.